Role of Medical Imaging in Cancers

• Eará dahkkit: Fanti, Stefano (Doaimmaheaddji), Evangelista, Laura (Doaimmaheaddji)
• Materiálatiipa: Elektrovnnalaš Girjji oassi
• Giella: eaŋgalasgiella
• Almmustuhtton: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Fáttát: Medicine; positron emission tomography; head and neck neoplasms; neovascularization; pathologic; PET/CT; urothelial carcinoma; bladder cancer; upper tract urothelial carcinoma; survival; PET; PSMA; prostate; DCFPyL; DCFBC; PSMA-1007; ovarian cancer; relapse; SUVmax; targeted therapy; prognosis; soft tissue sarcoma (STS); pazopanib; dynamic 18F-FDG PET/CT; SUV; two-tissue compartment model; magnetic resonance imaging; machine learning; diffusion; perfusion; texture analysis; squamous cell carcinoma of the head and neck; diffusion-weighted imaging; malignant pleural mesothelioma; pleural dissemination; empyema; pleural effusion; mCRPC; SPECT/CT; Computer-assisted diagnosis; XOFIGO; Therapy response assessment; circulating miRNAs; breast cancer; imaging parameters; PET/MRI; biomarkers; triple negative breast cancer; VCAM-1; SPECT imaging; sdAbs; Hounsfield unit; computed tomography; adipose tissue; precision oncology; FDG-PET/CT; PERCIST; metastatic breast cancer; prostate cancer; 18F-FACBC; recurrence; meta-analysis; review; meningioma; somatostatin receptor; neuroimaging; radionuclide therapy; breast; imaging; marker; radiomics; Yin Yang 1; PDAC; Mesothelin; noninvasive imaging; receptor status; molecular imaging; nuclear medicine; guidelines; overutilization; epistemology; consensus; mantle cell lymphoma; 18F-FDG PET/CT; Deauville criteria; Radium-223; FDG; castrate resistant prostate cancer; programmed cell death 1 receptor; diagnostic imaging; CTLA-4 Antigen; Immunotherapy; Adoptive; radioactive tracers; radionuclide imaging; CD8-Positive T-Lymphocytes; PI-RADS; diffusion kurtosis imaging; dynamic contrast-enhanced magnetic resonance imaging; 68Gallium-PSMA PET/CT; prostate-specific-antigen; PSA kinetics thresholds; biochemical recurrence; optimal cutoff level; non-small-cell lung cancer; circulating tumor cells; immunotherapy; response to treatment; head and neck cancer; HPV; EBV; p16; Molecular imaging; miRNA expression; radiogenomics; radiomic; diagnosis; biomarker; glioblastoma; radiation therapy; MRI; diffusion tensor imaging; Hodgkin lymphoma; diffuse large B-cell lymphoma; staging; response assessment; locally advanced cervical cancer; concurrent chemoradiotherapy; treatment response; follow up; cystic tumor; International Consensus Guidelines; intraductal papillary mucinous neoplasms; pancreatic neoplasms; PD-1; PD-L1; response to therapy; NSCLC; positron-emission tomography; single-photon emission computed tomography; immune checkpoint inhibitors; gold nanoparticle; heat shock protein 70; spectral-CT; n/a
• Liŋkkat: DOAB: download the publication; DOAB: description of the publication